An evaluation and comparison of current FDA-approved treatments for obesity by Bapatla, Neha
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
An evaluation and comparison of
current FDA-approved treatments
for obesity
https://hdl.handle.net/2144/30872
Boston University
	 	 	
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
AN EVALUATION AND COMPARISON OF CURRENT FDA-APPROVED 
 
TREATMENTS FOR OBESITY 
 
 
 
 
by 
 
 
 
 
NEHA BAPATLA 
 
B.S., University of Florida, 2016 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2018  
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2018 by 
 NEHA BAPATLA 
 All rights reserved  
	 	 	
Approved by 
 
 
 
 
First Reader   
 Gwynneth D. Offner, Ph.D. 
 Associate Professor of Medicine 
 
 
Second Reader   
 Jean L. Spencer, Ph.D. 
 Instructor of Biochemistry 
 
 
 
 
		 iv 
AN EVALUATION AND COMPARISON OF CURRENT FDA-APPROVED 
TREATMENTS FOR OBESITY 
NEHA BAPATLA 
ABSTRACT 
 As society adopts a sedentary lifestyle coupled with increased energy intake, 
obesity continues to spread pervasively throughout the world. It poses a strong public 
health threat due to the development of related comorbidities in individuals, such as 
diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. Prior to the new 
millennium, treatment of obesity included lifestyle modifications or bariatric surgery. 
However, this alienated a large subset of the population who were unable to lose weight 
with behavioral changes alone but not obese enough to qualify for bariatric surgery. 
Thus, the need for an intermediate therapeutic method existed. Short-term 
pharmacotherapy, such as orlistat, was developed as a potential treatment option for 
weight loss. However, as the years passed, scientists began targeting the central nervous 
system (CNS) and gastrointestinal systems to develop long-term medications. As a result, 
liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/ 
topiramate extended-release became FDA-approved for long-term treatment of obesity. 
Each drug acts on a specific part of the CNS to modulate appetite and cause decreased 
food intake in patients. Clinical trials conducted on these medications found 
phentermine/topiramate extended-release to cause the greatest weight loss. However, 
none of the medications emerged as a first-line treatment option for weight loss. With a 
myriad of side effects and contraindications, clinicians must practice personalized 
		 v 
medicine to prescribe certain drugs for patients. Furthermore, because these medications 
have been relatively recently approved, research on long-term effects of these 
medications on the human body is not available. Despite this, the emergence of 
pharmacotherapy in conjunction with lifestyle modifications in treating obesity has been 
positive. It has created a necessary step in the direction of reducing obesity prevalence 
worldwide and thus a proactive step in promoting the health of individuals.    
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I. INTRODUCTION 
Obesity as a Public Health Threat 
In recent decades, obesity has emerged as a major public health threat, owed 
largely to the pervasive “obesogenic” environment that dominates today’s society. This 
trend is marked by increased access to calorie-rich food, such as fast food, and adoption 
of inactive habits. With the emergence of fast food restaurants and easily accessible, 
nutrition-poor foods, waistlines have resultantly increased. This global shift toward an 
energy-rich and sedentary lifestyle has led to an incredible pandemic that affects public 
health and economic growth simultaneously (Li et al., 2017). Figure 1 provides a visual 
image of the increasing prevalence of obesity worldwide. Although Third World 
countries are affected, developing and developed nations, shown in darker colors on the 
map, contribute greater to this public health threat. Various governmental entities have 
allocated time and effort in studying the increasing prevalence of obesity. For example, 
the World Health Organization (WHO) has found that obesity is the fifth leading cause of 
death in the world, claiming responsibility for 2.8 million adult deaths per year (Leung et 
al., 2017). In addition, data from the National Health and Nutrition Examination Survey 
have shown that more than one-third of adults in the United States (US) are obese 
(Sandouk & Lansang, 2017). Data from studies conducted by the Center for Disease 
Control (CDC) have validated the beliefs that diabetes and obesity are at epidemic levels, 
specifically stating that adults in the US have a 40% lifetime risk of developing diabetes, 
a well-known comorbidity of obesity (Sandouk & Lansang, 2017). 
	2 
 
Figure 1. Worldwide prevalence of obesity for males of ages 18+, 2014 (age 
standardized estimate). Although obesity presents a threat worldwide, this map shows 
its great effect on the United States in relation to the rest of the world. Nations that are 
well developed seem to have increased prevalence of obesity. Taken from Sheikh et al. 
(2017).  
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It is especially important to recognize the full breadth of problems that obesity 
creates. On the health spectrum, obesity serves as a “gateway disease,” often leading to 
the development of many other chronic diseases such as insulin resistance, hepatic 
steatosis, pancreatitis, lipotoxicity, type 2 diabetes mellitus (T2DM), and cardiovascular 
diseases (CVD) (Li et al., 2017). Each of these diseases leads to a series of complications 
that are difficult to manage and sometimes fatal. Figure 2 shows how conditions such as 
insulin resistance and chronic increase in inflammation directly lead to disease states such 
as T2DM and dyslipidemia.  
Treatment of these comorbidities places a large burden on current and future 
generations, as society is forced to keep up with the ever-increasing costs of healthcare 
(Leung et al., 2017). In this respect, obesity poses a large economic burden that is not 
exclusive to affecting the US economy. In 2014, it was reported that the costs associated 
with treating obesity and its comorbidities were $2 trillion US dollars (USD), or 2.8% of 
the global gross domestic product (GDP) (Tremmel et al., 2017). Although the costs 
associated with treating obesity directly affect the economy, there are other contributing 
factors that affect the economy indirectly (Kalantari et al., 2016). For example, obesity 
can impose costs at a lower, individual level. Lost workdays, lower productivity at work, 
and permanent disability as a result of complications from obesity and its comorbidities 
are responsible for affecting economic growth (Tremmel et al., 2017).  
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Figure 2. Adiposity-associated major risk factors for developing HF and other 
weight-related comorbidities. Chronic inflammation of adipocytes leads to a variety of 
conditions, such as insulin resistance, that ultimately lead to the development of diseases 
like diabetes, lipotoxicity, and dyslipidemia. This ultimately leads to heart failure. HF = 
heart failure; RAAS = renin-angiotensin-aldosterone system; SNS = sympathetic nervous 
system. Taken from Gadde et al. (2018). 
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Trends over the past few decades have shown a positive relationship between 
prevalence of obesity and costs incurred from treatment. Data produced from 1980 to 
2014 have shown that pervasiveness of obesity has more than doubled in this time span 
(Mancini & de Melo, 2017). In 2014, WHO reported that 1.9 billion adults were 
overweight, and of these individuals, over 600 million were obese (Mancini & de Melo, 
2017). It has been forecasted that obesity will rise by at least 33% within the next two 
decades if changes are not made (Gray et al., 2015). Even more alarming data anticipate 
that severe obesity, categorized by a body mass index (BMI) between 35 and 39.99 
kilograms per meter squared (kg/m2), will rise by 130% in that same 20-year time period 
(Gray et al., 2015).  
Concurrently, medical costs have been increasing rapidly to keep up with the 
treatments necessary for obesity and its comorbidities. For example, in 2008, estimated 
costs for medical treatment were $147 billion in the US alone (Nuffer & Trujillo, 2015). 
These costs have grown exponentially since then, with estimates of medical costs of 
obesity-related treatments reaching $209.7 billion in the US (Mancini & de Melo, 2017). 
This amount corresponds to about 20.6% of the national health expenditure in 2014 
(Mancini & de Melo, 2017). Thus, it is evident that obesity poses a strong threat in the 
economic arena. All of these statistics emerge to paint a stark picture—the reality that a 
potentially preventable condition leads to the development of chronic diseases and 
resultantly places a huge economic burden on nations that could allocate these funds for 
research or other programs.  
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Obesity Defined  
The clinical characterization of obesity is best defined by WHO as an “excessive 
body fat accumulation that is associated with clear risks to health” (Meldrum et al., 2017; 
Morris et al., 2015). The body fat that WHO specifically refers to is called white adipose 
tissue (WAT). The imbalance of energy consumption and expenditure, that is, more 
caloric intake than energy release, directly contributes to WAT deposition and excess 
body fat accumulation (Nuffer & Trujillo, 2015). This state of high energy is aggravated 
by the obesogenic environment that promotes high caloric intake and reduced physical 
activity. Although the increased accumulation of WAT is not preferred, it is specifically 
the deposition of central adipose tissue that leads to a higher risk of many chronic 
diseases. WAT is divided into subcutaneous adipose tissue (SAT) and visceral adipose 
tissue (VAT). Although SAT encompasses 80% of adipose tissue, VAT is more 
metabolically active and thus more responsible and a stronger predictor for obesity-
related mortality (Frasca & Blomberg, 2017). For example, studies have shown that 
people who deposit more VAT than SAT have a higher risk for the development of 
metabolic diseases such as dyslipidemia, insulin resistance, and central adiposity (Li et 
al., 2017; Meldrum et al., 2017).  
In addition, obesity is considered a low-grade, chronic inflammatory disease 
(Stolarczyk, 2017). There are many molecular pathways responsible for the development 
of chronic diseases. For example, the hypertrophy of adipocytes and the increase in 
proinflammatory adipokines like tumor necrosis factor-alpha (TNF-alpha) and 
interleukin-6 (IL-6) lead to an infiltration of adipose tissue by macrophages (Stolarczyk, 
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2017). The increased presence of macrophages ultimately leads to insulin resistance 
(Stolarczyk, 2017). This pathway is one of many involving the immune system. Chronic 
activation of the innate immune system in adipose tissue is also responsible for 
pathologic conditions like psoriasis, cancer, and inflammatory bowel disease (IBD) 
(Frasca & Blomberg, 2017). Figure 3 demonstrates how an imbalance in leptin secretion 
causes the chronic activation of the immune system, which leads to the development of 
insulin resistance.  
In addition to its role as a reservoir for energy, adipose tissue is considered an 
immune organ (Stolarczyk, 2017). This is evident by its ability to secrete large numbers 
of proteins that are responsible for regulating metabolism, energy intake, and fat storage 
(Stolarczyk, 2017). The proteins that are secreted from adipose tissue are specifically 
referred to as adipokines and include leptin (LEP), adiponectin, TNF-alpha, and IL-6 
(Stolarczyk, 2017). Mutations that affect the genes coding for these adipokines and their 
receptors, such as LEP and its receptor, are shown to be linked to morbid obesity 
(Stolarczyk, 2017). 
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Figure 3. Cycle demonstrating effect of mutations in leptin and leptin receptor on 
insulin sensitivity and resistance. During insulin sensitive conditions, immune cells 
such as regulatory T and B cells and Th2 CD4+ T cells infiltrate adipose tissue. With an 
increase in energy intake, there is an accumulation of lipids within adipocytes that results 
in an imbalance in leptin secretion in adipose tissue. This leads to infiltration of Th1 
CD4+ T cells, B cells, natural killer cells, and macrophages, which perpetuates an 
inflammatory environment. Inflammation directly contributes to the development of 
insulin resistance. In order to restore normal insulin sensitivity, cytokines like IL-33, IL-
4, or IL-13 can convert white adipocytes into beige adipocytes. These beige adipocytes 
are able to burn lipids and thus restore normal insulin sensitivity through reduction of the 
proinflammatory environment. Breg = regulatory B; CD = cluster of differentiation; IFN 
= interferon; IL =interleukin; ILC = innate lymphoid cell; NK = natural killer; Th = T 
helper; TNF = tumor necrosis factor; Treg = regulatory T. Taken from Stolarczyk (2017). 
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Despite the problems associated with using BMI as the definitive scale to define 
obesity, such as the inability to differentiate between dangerous adipose tissue and less 
harmful muscle, BMI is used as a general guideline to characterize body fat (Meldrum et 
al., 2017). BMI is measured as kilograms (kg) divided by meters (m) squared. These BMI 
categories range from normal to overweight to increasing stages of obese. An individual 
is categorized as overweight when his or her BMI is between 25 and 29.99 kg/m2 (Barte 
et al., 2014). Class 1 obesity is defined as a BMI between 30 and 34.99 kg/m2, and class 2 
obesity is defined as a BMI between 35 and 39.99 kg/m2 (Barte et al., 2014). Class 2 
obesity is also referred to as severe obesity, and a BMI above 40 kg/m2 is classified as 
morbid obesity (Meldrum et al., 2017). Although BMI is not a definitive method to 
classify body fat, it is a useful tool to generally characterize obesity.  
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Genetic Versus Environmental Factors  
Understanding the interplay of genetic and environmental factors in the 
development of obesity in individuals is important in learning how to best treat this 
condition (Sheikh et al., 2017). Although researchers and clinicians can consider genetics 
and lifestyle as separate contributors to obesity, the interactions of these factors play a 
much stronger role in its development.  
On the genetic spectrum, obesity can be considered a heritable disease (Sheikh et 
al., 2017). For example, when compared with children having non-obese parents, children 
whose parents were both obese had a significantly higher risk for being obese 
(Albuquerque et al., 2017). Twin studies have further suggested that genetics may 
contribute between 50% and 80% of obesity in families (Sheikh et al., 2017). However, 
large-scale genome-wide association studies (GWAS) revealed that hundreds of BMI-
associated genetic loci could only explain about 2.7% of BMI variation (Zhao et al., 
2017). In other words, even though the heritability of BMI ranges between 50% and 80%, 
the genetic variants could only account for 2.7% of BMI variation (Zhao et al., 2017). 
Thus, the influence of gene-environment interactions as contributing factors for this 
missing heritability should be considered (Zhao et al., 2017). 
In addition, obesity can be divided into monogenic obesity (mutation in one gene) 
and polygenic obesity (mutations in several genes). The genes responsible for these types 
of obesity include LEP, leptin receptor (LEPR), proopiomelanocortin (POMC), and 
prohormone convertase 1 (PCSK1) (Sheikh et al., 2017). Monogenic obesity is often 
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associated with severe obesity in children, accounting for 5% of obesity cases (Sheikh et 
al., 2017). 
The influence of environmental factors on obesity is important in the discussion 
of appropriate treatment plans. It is generally accepted that genetics plays a lesser role 
than the environment in the development of obesity (Meldrum et al., 2017). The 
“obesogenic environment,” which refers to the cheap and easy availability of high-calorie 
foods and a sedentary lifestyle, is a prime example of how outside factors directly 
contribute to increased fat accumulation (Sheikh et al., 2017). Obesity, in this sense, 
occurs through a positive energy balance characterized by an imbalance in the energy 
intake and the energy expenditure of the body (Sheikh et al., 2017). On a physiological 
level, this positive energy balance is dangerous because it favors the storage of energy in 
the form of fatty acids (Sheikh et al., 2017). These fatty acids are normally stored in 
adipose tissues to be used by the body in times of energy deprivation. However, in obese 
and overweight individuals, the body continues to store excess amounts of energy instead 
of using the already stored energy, which leads to an even greater imbalance in the 
positive energy balance (Sheikh et al., 2017).   
There are many contributors to a positive energy balance, such as lower 
socioeconomic status (SES) and psychosocial factors (Zhao et al., 2017). The relationship 
between obesity and these factors is mediated by nutrition and exercise (Zhao et al., 
2017). For example, those individuals who are in the lower SES bracket often have less 
access to nutritious foods and are more likely to choose fast food because of accessibility. 
Others who skip breakfast may struggle with weight loss as a result of a slower 
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metabolism, and their inactivity directly corresponds to the development of obesity (Zhao 
et al., 2017). Recognizing these factors as strong contributors to obesity is important in 
developing an effective BMI treatment strategy (Zhao et al., 2017). Although every 
patient is unique with differing contributions from genetic and environmental factors, 
clinicians can work with the knowledge gained from research to formulate holistic 
treatment plans that are specifically tailored to each individual.  
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History of Obesity Treatment 
Traditionally, anti-obesity treatments consisted of lifestyle counseling and 
behavioral changes or bariatric surgery. In cases of moderate obesity, the first line of 
treatment often included modifications to diet and an increase in exercise (Manigault & 
Thurston, 2016). Figure 4 shows the current stepwise management of obesity. The 
diagram indicates that after behavioral modifications, there were no other options for 
individuals prior to the development of pharmacotherapy. Although they were obese, 
these individuals were not morbidly obese and thus not approved to undergo bariatric 
surgery. Consequently, there was a need for a more aggressive method to permanently 
treat obesity that was approved for moderately obese individuals. 
  Those who suffered from morbid obesity also begin with lifestyle counseling but 
are given the option of bariatric surgery if behavioral changes are not successful. 
Bariatric surgery encompasses a variety of procedures that include reducing the size of 
the stomach with the insertion of a gastric band, removing a portion of the stomach, or 
rerouting the small intestine to a small gastric pouch. Although bariatric surgery was 
touted as a permanent alternative to weight-loss treatment, a small percentage of patients 
regained the weight, and the procedure was deemed unsuccessful. Furthermore, bariatric 
surgery is an invasive and expensive procedure to perform (Pappachan & Viswanath, 
2017). In some cases, patients suffered long-term adverse health consequences from the 
surgery (Pappachan & Viswanath, 2017). Table 1 details the incidence of various adverse 
events in populations of patients over or under the age of 60. In the first 90 days 
succeeding surgery, patients experienced events such as anastomotic leak, internal hernia, 
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deep vein thrombosis, and pulmonary complication. After 90 days post surgery, 
individuals had the risk of persistent diarrhea, nutritional deficiency, and reoperation.  
 
 
Figure 4. Stepwise management of obesity in adults. A series of factors are considered 
by clinicians before deciding the course of treatment for an individual. Before 
considering pharmacotherapy or bariatric surgery as an optional treatment, clinicians 
assess for BMI, depression and mood disorders, and comorbidities. Initially, lifestyle 
modifications are considered. Then, clinicians must assess if lifestyle modifications are 
adequate for the patient; if not, pharmacotherapy or bariatric surgery is considered. BMI 
= body mass index. Taken from Dietz et al. (2015). 
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Table 1. Adverse Postsurgery Outcomes for Bariatric Surgerya  
 
Postsurgery Adverse Outcome 
% of Population by 
Patient Age 
≤ 60 years > 60 years 
Early (≤90 days) Sleeve or anastomotic leak  0.5 0.5 
 Internal hernia 0.6 0.5 
 Sleeve or anastomosis stenosis 1.8 0.5 
 Pulmonary complication 0.3 0.5 
 Deep vein thrombosis 0.1 --- 
Late (>90 days) Persistent diarrhea 0.7 0.5 
 Nutritional deficiency 2.5 2.9 
 Reoperation (revision or repair)  0.4 0.5 
 Death not related to surgery 0.1 1.0 
 
aThis table shows the adverse outcomes that patients experience either immediately after 
bariatric surgery or later in their recovery. Taken from Kaplan (2018).   
 
Despite these issues with bariatric surgery, the benefits outweigh the risks for 
some patients who suffered from morbid obesity. The chance at an improvement in 
quality of life drives patients to choose this procedure. Moreover, studies conducted on 
patients postsurgery have shown that a large proportion of patients undergo immediate 
remission of diabetes (Pappachan & Viswanath, 2017). 
Lifestyle modifications and bariatric surgery lie on opposing ends of the spectrum 
for obesity treatment. Pharmacotherapy, however, offers a moderate yet aggressive 
method of tackling obesity in a larger population of individuals. As the use of 
pharmacotherapy in the treatment of obesity becomes a more popular option for those 
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struggling with long-term weight loss, individuals should consider the history of obesity 
treatment once the Food and Drug Administration (FDA) began approval of several 
drugs.  
In 1992, the authority for oversight and approval of anti-obesity drugs was given 
to the FDA (Gadde & Pritham, 2017). At this time, very few drugs were approved for 
treatment, and none of them were approved for long-term usage. Some of these drugs 
were phentermine, diethylpropion, phendimetrazine, and benzphetamine, which were 
approved in the US for short-term usage of only three months (Gadde & Pritham, 2017). 
All of these medications shared similar mechanistic properties and structural properties 
with amphetamine (Gadde & Pritham, 2017). In the same manner that amphetamine acted 
in the body, these anti-obesity medications functioned at the level of the central nervous 
system (CNS) by enhancing catecholamine turnover and thus suppressing appetite 
(Gadde & Pritham, 2017).   
The need for a longer-term weight-loss medication was evident, and thus orlistat 
was developed. Orlistat received FDA approval in 1998 and became available over the 
counter (OTC) in 2008 (Kim, 2016). It remained the only anti-obesity treatment on the 
market for long-term treatment until 2012 (Kim, 2016). Unlike the mechanistic action of 
the drugs previously described, orlistat acted at the level of the gut by reducing dietary fat 
absorption through selective inhibition of pancreatic lipase (Gadde & Pritham, 2017; 
Kim, 2016). In a double-blind randomized controlled trial (RCT) of 3340 obese 
individuals treated with orlistat (120 mg three times daily), results showed that there was 
a 3.6 kg weight loss compared with 1.4 kg in the placebo arm of the study (Kim, 2016). 
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This finding suggests that orlistat offers moderate weight loss. Although orlistat confers 
benefits in weight loss, patients suffer from unpleasant side effects such as diarrhea, 
flatulence, and fecal incontinence (Kim, 2016). Furthermore, in clinical trials orlistat has 
been associated with cases of hepatitis that may result in liver transplantation or death 
(Kim, 2016). 
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Specific Aims 
Many new medications have spawned from the success of orlistat as a long-term 
obesity medication. Currently, there are four drugs that are FDA-approved and offered 
for clinical treatment: liraglutide, lorcaserin, phentermine/topiramate extended-release 
(PHEN/TPM ER), and naltrexone/bupropion extended-release (NB) (Nuffer et al., 2016). 
The specific aim of this study is to identify a primary medication for obesity treatment. 
This work aims to achieve this goal through carrying out a comprehensive review of the 
literature to evaluate medications that are currently FDA-approved for long-term obesity 
treatment and to compare the efficacy of pharmacotherapy for obesity. The information 
gained from this study can provide insight to clinicians on how to best approach the 
management of obesity in patients. The following sections evaluate each medication 
separately, considering history of its discovery, mechanism of action, effects on weight 
loss and obesity-related comorbidities, and side effects. In addition, there is a comparison 
of the different medications and their efficacies.  
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II. CURRENT TREATMENT OPTIONS 
 
Traditionally, lifestyle modifications and bariatric surgery have been prime 
methods for tackling obesity in the population. However, this has alienated a huge 
proportion of obese individuals who are unable to maintain substantial weight loss with 
behavioral changes alone but are ineligible for bariatric surgery. As a result, 
pharmacotherapy has recently emerged as an option to treat a larger population with 
better results. Pharmacotherapy targets patients with a BMI of greater than 30 kg/m2 or a 
BMI greater than 27 kg/m2 with related comorbidities such as T2DM, CVD, and 
dyslipidemia (Gadde & Pritham, 2017). FDA approval of such medications requires 
clinically meaningful weight loss, which is defined as at least 5% mean weight loss after 
one year of treatment for 35% of the patients (Nuffer et al., 2016). The FDA recommends 
that a drug be discontinued if less than 5% weight loss is achieved within the first 16 
weeks of starting the medication (Golden, 2017). It is unlikely that meaningful weight 
loss will occur after this time period if it has not already occurred. Individuals on these 
weight-loss medications tend to lose between 3% and 10% of weight, but this often 
requires the continual use of medication for weight loss to be maintained (Kim, 2016). 
Thus, it is often suggested that behavioral modifications be made in conjunction with 
pharmacotherapy in order to sustain weight loss when taken off the drug.  
Clinicians must consider a number of factors when deciding if medication is 
appropriate for a patient. Clinical trials conducted on obesity medications often have an 
accompanying change on caloric intake and activity levels; thus the data reported are 
dependent on lifestyle modifications (Kim, 2016). In order for these results to translate 
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into real-life changes, clinicians must advocate behavioral changes for obesity 
medications to have a full impact. After initiating treatment, clinicians must monitor 
weight loss closely to determine if it has little or no benefit (Kim, 2016). Often this is 
evident almost immediately because weight loss with medications occurs quickly. In 
addition, clinical trials conducted on these medications frequently include a population 
with a BMI between 27 kg/m2 and 45 kg/m2 (Kim, 2016). The data from these trials are 
important to consider when treating patients of a similar BMI, but the effect of this 
treatment on morbidly obese individuals is unknown (Kim, 2016). In this case, clinicians 
may feel inclined to prescribe medication to initiate weight loss and schedule bariatric 
surgery to continue permanent weight loss (Kim, 2016). A particularly important factor to 
consider when prescribing obesity medication is the assumption that a patient may regain 
all lost weight after stopping the medication (Kim, 2016). This is based on the fact that 
many of the clinical trials do not contain drug washout data (Kim, 2016). Furthermore, 
long-term effects of drugs like lorcaserin and liraglutide are unknown (Kim, 2016). 
Clinicians must consider whether these risks outweigh the benefit of improving quality of 
life through substantial weight loss. 
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Liraglutide: GLP-1 and the Incretin Effect 
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, acting at GLP-
1 receptors (GLP-1Rs) in the body to initiate a series of physiological effects that control 
appetite and thus cause weight loss. A receptor agonist is defined as a compound with an 
alternative structure that mimics the action of the native compound (Angeli & Shannon, 
2014). GLP-1 acts at areas in the hypothalamus or other brain regions that are responsible 
for regulation of appetite, and controls effects on the gut to reduce food intake by vagal 
signaling and delayed gastric emptying (Nuffer et al., 2016). Figure 5 shows how GLP-1 
acts at the gastrointestinal system, adipose tissue, and the pancreas to regulate appetite 
and food intake. For example, the GLP-1 action on the gastrointestinal tract promotes 
decreased motility and gastric emptying, which results in the individual feeling full for a 
longer period of time.  
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Figure 5. Action of GLP-1 and GIP in the peripheral tissues. GIP and GLP-1 act at 
certain tissues in the body to promote decreased food intake and loss in appetite. GIP = 
gastric inhibitory peptide; GLP-1 = glucagon-like peptide-1. Taken from Skow, 
Bergmann, & Knop (2016).  
 
GLP-1 is an incretin hormone, defined by its ability to induce glucose-dependent 
insulin secretion and reduce glucagon secretion simultaneously (Santilli et al., 2017). 
This action is characterized as the “incretin effect.” 
GLP-1 was discovered after gastric inhibitory polypeptide (GIP), another incretin 
hormone that was isolated from the crude extracts of porcine small intestine (Graaf et al., 
2016). Scientists who conducted experiments on GIP noticed that it could stimulate 
insulin secretion in animals and humans (Graaf et al., 2016). However, when GIP was 
tested with antibodies against GIP, the incretin effect was not abolished, which suggested 
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the presence of another gut insulinotropic factor (Graaf et al., 2016). In 1981, the 
translational products of messenger RNA (mRNA) were isolated from pancreatic islets of 
anglerfish, and GLP-1 was resultantly discovered (Graaf et al., 2016).  
GLP-1 is a peptide hormone that is released from enteroendocrine L cells in the 
distal intestine, alpha cells in the pancreas, and the CNS (Graaf et al., 2016). The 
proglucagon gene is specifically expressed in the L cells of the small intestine, the alpha 
cells of the pancreas, and the neurons in the caudal brainstem and hypothalamus (Graaf et 
al., 2016). The manner in which the gene product is cleaved and the proteins resultantly 
released from post-translational modifications is unique to the location in which cleavage 
occurs. For example, the proglucagon gene expressed in the pancreas creates a protein 
that releases glicentin-related pancreatic peptide, glucagon, intervening peptide 1 (IP1), 
and a major proglucagon fragment containing GLP-1, IP1, and glucagon-like peptide-2 
(GLP-2) (Graaf et al., 2016). Cleavage of this gene in the small intestine and the CNS 
creates glicentin, oxyntomodulin, GLP-1, IP1, and GLP-2 (Graaf et al., 2016). 
Endogenous GLP-1 exists in two forms in the body, GLP-1(7-36 amide) and GLP-1(7-37) 
(Graaf et al., 2016). Whereas both forms of endogenous GLP-1 may have similar biologic 
activities, the amide form of GLP-1 appears to have slightly improved stability in 
circulation (Graaf et al., 2016).  
GLP-1 binds to GLP-1R in the peripheral tissues, specifically at the pancreatic 
islet alpha and beta cells, nervous system, heart, kidney, vascular smooth muscle cells, 
endothelial cells, and macrophages (Angeli & Shannon, 2014). GLP-1R expression in the 
brain is important because of its presence in hypothalamic areas that control energy 
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homeostasis, such as the arcuate nucleus, paraventricular nucleus, and the dorsomedial 
nucleus (Graaf et al., 2016). Animal studies conducted on GLP-1 activity promote the 
idea that GLP-1R action on POMC/cocaine-amphetamine-regulated transcript (CART)-
expressing arcuate neurons affects liraglutide-mediated weight loss (Mancini & de Melo, 
2017). This is shown by the ability of GLP-1 to directly stimulate POMC/CART neurons 
and indirectly inhibit gamma-aminobutyric acid (GABA)-dependent signaling in neurons 
expressing neuropeptide Y (NPY) and agouti-related protein (AgRP) (Mancini & de 
Melo, 2017). 
GLP-1R is a G-protein-coupled receptor (GPCR) that acts mechanistically to 
stimulate adenylate cyclase, cyclic adenosine monophosphate (cAMP), protein kinase A 
(PKA), and insulin biosynthesis (Angeli & Shannon, 2014). Through the combined 
activation of GLP-1R in the central and peripheral nervous systems, the receptor 
promotes decreased gut motility and slowed gastric emptying to regulate food intake and 
thus body weight (Skow et al., 2016). Although the way in which GLP-1 mechanistically 
acts to control appetite and reduce body weight is disputed, crosstalk between GPCRs 
and insulin growth factor-I (IGF-I) signaling has been suggested as the way in which 
GLP-1 works. One theory is that activation of IGF-I receptor expression and signaling 
may play a role in the actions exerted by incretin hormone on B cells in the pancreas 
(Santilli et al., 2017). In this theory, GLP-1 increases the activity of IGF-I/insulin growth 
factor-II (IGF-II) receptor autocrine loops, which potentially protects B cells from 
undergoing apoptosis (Santilli et al., 2017). Furthermore, adipocytes from SAT and VAT 
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express IGF-I/IGF-II receptors, which suggests a role in the modulation of body fat 
distribution (Santilli et al., 2017).   
GLP-1 is secreted at low basal levels during the fasting state and is immediately 
elevated in the presence of glucose (Angeli & Shannon, 2014). The release of insulin in 
response to glucose, as a part of the “incretin effect,” is elevated when glucose is 
administered orally rather than intravenously (Graaf et al., 2016). However, GLP-1 is 
unable to exert its influence in circulation for an extended period of time. Dipeptidyl 
peptidase-4 (DPP-4) is a ubiquitous enzyme that acts immediately on GLP-1 to cleave 
and inactivate it within two minutes of GLP-1 entering circulation (Skow et al., 2016). 
Once GLP-1 is cleaved and inactivated, it is eliminated through the kidneys (Skow et al., 
2016). 
Because of the inability of GLP-1 to remain in circulation for more than two 
minutes, the molecular structure was modified to allow for an increase in its half-life. 
Modifications, such as the substitution of arginine on position 34 and the addition of a 
palmitic acid chain with glutamic acid spacer on the lysine residue on position 26, 
allowed for the pharmacokinetic effects to improve substantially (Mehta et al., 2016). 
Liraglutide—the modified form of GLP-1—remains in circulation for 13 hours, allowing 
it to exert its physiological effects for a longer duration (Mehta et al., 2016). Although 
liraglutide is resistant to DPP-4, this change in molecular structure reduces its potency in 
circulation because of decreased albumin binding (Angeli & Shannon, 2014). 
Liraglutide was initially marketed as Victoza (Nova Nordisk, Denmark) at 1.8 mg 
for treatment of T2DM (Mehta et al., 2016). However, in clinical trials, researchers 
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observed that patients were additionally losing weight while on the medication. A few 
years later, liraglutide was FDA-approved as an obesity medication at a higher dose of 
3.0 mg (Mehta et al., 2016). This increased dose was marketed as Saxenda (Novo 
Nordisk, Denmark) (Mehta et al., 2016). Saxenda is the most recently FDA-approved 
medication for treatment of obesity. The drug is marketed for treating chronic weight 
management in patients with a BMI over 30 kg/m2 or with a BMI over 27 kg/m2 and a 
related comorbidity (Mehta et al., 2016). It is administered as a subcutaneous injection in 
the abdomen, thigh, or upper arm (Gadde & Pritham, 2017; Mehta et al., 2016). The 
doses are given in a titration schedule in order to reduce adverse side effects that patients 
may feel. These side effects tend to be gastrointestinal in nature. Dosage starts at 0.6 mg 
and increases by 0.6 mg weekly until the maximum dose is achieved (Gadde & Pritham, 
2017).  
The most common reported side effect is nausea, which disappears quickly. Other 
adverse events noted are vomiting, hypoglycemia, diarrhea, constipation, headache, 
fatigue, dizziness, and abdominal pain (Mehta et al., 2016). In the preclinical 
development stage of liraglutide, there was a significant incidence of medullary thyroid 
cancer in rats and mice (Meier, 2012). Although this was not reported in humans, 
liraglutide is contraindicated in patients with a family history of thyroid cancer and 
multiple endocrine neoplasia type II (MEN II) (Meier, 2012).  
There are many other shortcomings surrounding the use of liraglutide. First and 
foremost, the cost of the drug is higher than the price of other weight-loss medications. 
The inability to continue treatment would lead to possible regaining of weight if 
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behavioral changes were not initiated. Moreover, the need for daily subcutaneous 
injections complicates the issue of compliance in patients who are uncomfortable with 
needles (Dietz et al., 2015).  
However, these factors must be weighed against the benefits that patients 
experience on liraglutide. It is hypothesized that liraglutide acts to reduce weight through 
a combination of effects on the brain and gastrointestinal system (Dietz et al., 2015). In a 
study conducted on emotional eating, researchers speculated that individuals who are 
prone to emotional eating have an increased neural response in anticipation to food intake 
or when viewing visual food cues, and that overeating could lead to hyperactivation of 
appetite- and reward-related brain areas in response to the anticipation of palatable food 
(van Bloemendaal et al., 2015). This study directly suggested that emotional eaters are 
less sensitive to physiological signs that are responsible for regulating satiety, such as 
GLP-1 (van Bloemendaal et al., 2015). Thus, this medication provides an extremely 
beneficial approach to treating a large population of patients who struggle with obesity 
due to imbalance in their appetite- and reward-related brain areas. Furthermore, treatment 
with GLP-1 was shown to have cardiovascular benefits, such as lowering blood pressure 
and increasing cardiac output (Skov, 2014). The ability of GLP-1 to induce natriuresis 
may explain its antihypertensive effect in patients (Skov, 2014). 
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Lorcaserin: Serotonin 2C Receptor 
Lorcaserin is a 5-hydroxytryptamine 2C (5-HT2C) receptor agonist, commonly 
known as a serotonin agonist (Farr et al., 2016). It primarily acts to alter energy balance 
in the body through reducing energy intake while not affecting energy expenditure 
(Redman & Ravussin, 2010). Through specific actions of the agonist on 5-HT2C receptors 
in the CNS, lorcaserin provokes hypophagia, thus reducing food intake and leading to 
weight loss (Dietz et al., 2015).  
The development of serotonergic drugs as a means for obesity treatment has been 
relatively recent. In the mid-1990s, research surrounding the development of a 5-HT2C 
receptor knockout mouse allowed for the identification of these types of drugs as a 
potential obesity therapeutic agent (Redman & Ravussin, 2010). Scientists found that 
when given 5-HT2C receptor agonists, these knockout mice failed to fully respond to the 
anorectic effects of the drug, such as decreased food intake (Redman & Ravussin, 2010). 
This provided evidence for the use of the 5-HT2C receptor as a potential target for food 
intake regulation (Redman & Ravussin, 2010). Another observation made by these 
researchers was the development of late-onset obesity with related comorbidities when 
the knockout mice were fed a high-fat diet (Redman & Ravussin, 2010). 
Further clinical proof can be found on the potency of serotonergic drugs in 
reducing body weight. Dexfenfluramine, an indirect 5-HT agonist marketed as Redux 
(Pfizer, Pennsylvania), was evaluated in studies which showed that elevating 5-HT was 
an effective method for treating obesity (Higgins et al., 2012). However, in patients 
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taking this drug, there were cases of cardiac valvulopathy that have since been associated 
with the activation of 5-HT2B receptors in cardiac tissue (Higgins et al., 2012). 
The shared homology of receptors in the 5-HT2 subclass has proven to be a 
challenge in developing drugs that will be highly selective for the 2C receptor. With an 
80% shared homology among 2A, 2B, and 2C subtypes, a drug had to be developed with 
increasingly specific action on the 2C receptors (Redman & Ravussin, 2010). Lorcaserin 
was developed as a highly selective 5-HT2C receptor agonist with properties that have 
over 100-fold selectivity for 2C receptors over 2B receptors and 15-fold selectivity for 
2C receptors over 2A receptors (Higgins et al., 2012). The 2B receptors are associated 
with the development of cardiac valvulopathy, and hallucinogens like LSD are 5-HT2A 
receptor agonists (Higgins et al., 2012). Thus, it was critical for lorcaserin to be highly 
selective for the 5-HT2C receptor. At therapeutic doses, lorcaserin is not generally 
associated with hallucinogenic activity or the development of cardiac valvulopathy 
(Higgins, et al., 2012). 
The mechanistic action of lorcaserin is primarily in the CNS, most specifically in 
the hypothalamus (Nuffer et al., 2016). The selective activation of 5-HT2C receptors in 
anorexigenic neurons leads to the activation of pathways that subsequently act to inhibit 
appetite stimulation and thus promote satiety in the human body (Nuffer et al., 2016). 
The 5-HT2C receptors are located in areas such as the choroid plexus, thalamus and 
hypothalamus, limbic structures, and extrapyramidal pathways (Smith et al., 2009). These 
receptors are essentially absent in peripheral tissues (Smith et al., 2009). The 5-HT2C 
receptors located in the hypothalamus are essential for the action of lorcaserin because 
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the hypothalamus is the major center responsible for regulation of hunger and food intake 
(Smith et al., 2009). 
When an individual ingests food, the 5-HT2C receptors in the hypothalamus are 
activated, causing depolarization of anorectic POMC neurons in the arcuate nucleus 
(Redman & Ravussin, 2010). This causes the release of α-melanocyte-stimulating 
hormone (α-MSH), which resultantly leads to the downstream activation of melanocortin 
4 receptors in the paraventricular hypothalamus (Adan, 2013). Lorcaserin takes 
advantage of this signaling pathway to promote satiety and cause decreased food intake 
in humans (Redman & Ravussin, 2010). 
Lorcaserin was FDA-approved as a long-term obesity treatment in 2012 (Kim, 
2016). It emerged on the market under the name Belviq (Arena Pharmaceuticals, 
California) (Kim, 2016). This drug is administered in two formulations: twice daily in 10 
mg tablets or once daily in a 20 mg extended-release tablet (Golden, 2017). Three RCTs 
found that treatment with lorcaserin achieved between 3% and 3.6% placebo-subtracted 
weight loss after one year (Gadde et al., 2018). These trials also showed that when 
lorcaserin was continued for a second year, nearly one-half of the weight that was lost 
was subsequently regained (Gadde et al., 2018). The FDA generally recommends that 
weight-loss medications should be discontinued within 12 weeks if patients achieve less 
than 5% of weight loss in that time period. However, recently published trials have 
shown that only 28% of patients achieved this amount of weight loss in 12 weeks with 
lorcaserin (Gadde et al., 2018). Thus, although lorcaserin is generally tolerated well 
among the population, the efficacy is relatively marginal (Gadde et al., 2018).  
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Side effects of lorcaserin include headache, dizziness, and nausea—all considered 
symptoms that are well tolerated (Kim, 2016). Patients with T2DM are cautioned when 
taking lorcaserin because additional adverse events can occur, such as hypoglycemia, 
cough, back pain, and fatigue (Golden, 2017). Furthermore, clinicians must consider the 
risk of serotonin syndrome in patients who also take selective serotonin reuptake 
inhibitors (SSRIs) (Nuffer et al., 2016). Serotonin syndrome- and neuroleptic malignant 
syndrome (NMS)-like reactions have been reported in patients who also take SSRIs, 
serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors 
(MAOIs), triptans, dextromethorphan, and St. John’s wort (Golden, 2017). In addition, 
cases of patients with valvular heart disease have been observed when taking other 
serotonergic drugs; thus, the FDA has required a cardiovascular outcomes trial (Gadde et 
al., 2018).  The CAMELLIA-TIMI trial is currently underway to evaluate the 
cardiovascular risk of lorcaserin (Golden, 2017). Because the FDA has classified 
lorcaserin as a Pregnancy Category X drug, it is contraindicated for use during pregnancy 
(Golden, 2017). Lorcaserin is also classified as a Schedule IV drug as a result of its 
potential to induce hallucinations and euphoria which could result in psychic dependence 
(Golden, 2017).   
Despite these factors, lorcaserin provides many benefits to patients. When 
compared with placebo treatment, lorcaserin treatment for a year led to reductions in 
waist circumference, blood pressure, total cholesterol, low-density lipoprotein (LDL) 
cholesterol, and triglycerides (Redman & Ravussin, 2010). Moreover, lorcaserin 
treatment led to significant improvement in insulin sensitivity as shown by reductions in 
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glycated hemoglobin, fasting glucose, and insulin (Redman & Ravussin, 2010). In 
addition to these improvements, there were significant reductions in inflammatory 
markers, high-sensitivity C-reactive protein, and fibrinogen after a year of treatment with 
lorcaserin compared with placebo (Redman & Ravussin, 2010). 
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Phentermine/Topiramate ER: Sympathomimetics and Antiepileptics  
In July 2012, the FDA approved the use of phentermine/topiramate extended-
release (PHEN/TPM ER) as a combination therapy for long-term treatment of obesity in 
individuals who are either obese or overweight with obesity-related comorbidities 
(Sweeting et al., 2014). The premise of combination therapy lies in its potential to use 
lower doses of the component medications while retaining comparable additive effects 
and simultaneously minimizing adverse reactions (Consentino et al., 2013). Combination 
therapy targets multiple complementary pathways that regulate energy homeostasis in 
order to overcome counterregulatory mechanisms that lead to regaining of weight 
(Sweeting et al., 2014). As a monotherapy, phentermine is a sympathomimetic amine that 
is used for treatment of short-term obesity (Garvey, 2013). It is prescribed as an 
immediate-release formulation that undergoes dissolution and absorption in the 
gastrointestinal tract (Jordan et al., 2014). As a short-term obesity medication, 
phentermine is approved for a dose of 15-37.5 mg per day for a 12-week treatment 
(Jordan et al., 2014). The second component, topiramate, is a sulfamate-substituted 
monosaccharide that is used as an antiepileptic agent (Garvey, 2013). It is also an 
immediate-release formulation that is primarily prescribed to treat epilepsy and prevent 
migraines, although it has secondary weight-loss effects (Jordan et al., 2014). As a 
combination therapy, PHEN/TPM ER is an effective obesity pharmacotherapy, with one 
study speculating that it was the most effective pharmacotherapy available for treatment 
of obesity (Sweeting et al., 2014). 
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Even though the mechanism of action of PHEN/TPM ER is unknown, the 
consideration of how the medications act separately may lead to a better understanding of 
the combined mechanism. Phentermine is believed to be an agent that promotes appetite 
suppression, although other CNS actions may potentially be involved as well (Garvey, 
2013). Phentermine is an atypical amphetamine analogue that acts to increase 
norepinephrine in the CNS (Jordan et al., 2014). Through its action on the CNS, 
phentermine is an agent that promotes appetite suppression (Garvey, 2013). However, it 
is not well understood how topiramate leads to weight loss. Evidence suggests that an 
energy-balance regulation is responsible (Garvey, 2013). Scientists believe that 
topiramate achieves weight loss through a variety of pathways such as modulation of 
voltage-gated ion channels, carbonic anhydrase inhibition, and inhibition of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate excitatory glutamate 
receptors (Garvey, 2013). Inhibition of carbonic anhydrase may affect taste and thus 
decrease food intake (Jordan et al., 2014). 
PHEN/TPM ER was initially marketed as Qnexa, but after obtaining FDA 
approval in July 2012, it was renamed Qsymia (Vivus, California) (Consentino et al., 
2013). This drug is prescribed as a once-daily combination of phentermine and 
topiramate ER (Consentino et al., 2013). The ER form of topiramate has a greater half-
life than regular topiramate, which correlates to a slower onset of action and a longer 
period of time to establish steady state (Consentino et al., 2013). The combination 
therapy of PHEN/TPM ER has been suggested to have a longer duration of action in the 
body as well as a better tolerability in patients compared with regular topiramate 
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(Consentino et al., 2013). This combination therapy can be given in four types of 
formulations: a starting dose of 3.75 mg/23 mg (phentermine/topiramate ER), a 
recommended dose of 7.5 mg/46 mg, a titration dose of 11.25 mg/69 mg, and a maximum 
dose of 15 mg/92 mg (Consentino et al., 2013). 
Multiple studies have been conducted to consider the safety of prescribing 
PHEN/TPM ER as a long-term obesity treatment. In one published review, researchers 
speculated that PHEN/TPM ER was the most effective available pharmacotherapy, 
although it was clarified that there were no head-to-head studies conducted at the time 
and that longer-term data would be required (Sweeting et al., 2014). This study also 
found that with mid- and full-dose PHEN/TPM ER, patients experienced mean reductions 
in weight of 8.5% and 9.2%, respectively (Sweeting et al., 2014). The EQUIP, 
CONQUER, and SEQUEL studies all found positive and significant results in patients 
using PHEN/TPM ER. The EQUIP study showed significant reduction in systolic and 
diastolic blood pressure as well as an improved lipid profile in individuals on a high dose 
of PHEN/TPM ER (Sweeting et al., 2014). The study group, however, was characterized 
by an overall lack of obesity-related comorbidities, so the results should be analyzed with 
this consideration (Sweeting et al., 2014). The CONQUER trial confirmed the significant 
improvements in systolic blood pressure, triglycerides, and high-density lipoprotein 
(HDL) cholesterol and also confirmed small, statistically significant reductions in 
diastolic blood pressure and LDL cholesterol with a full dose of PHEN/TPM ER 
(Sweeting et al., 2014). The SEQUEL trial continued to confirm the improvements in 
cardiometabolic disease in patients taking PHEN/TPM ER. The results showed 
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statistically significant reductions in systolic and diastolic blood pressure and 
improvements in glycemic control and lipid profiles (Sweeting et al., 2014). Collectively, 
these studies indicated that PHEN/TPM ER-associated weight loss could effectively 
prevent the progression to T2DM as well as improve glycaemia and blood pressure (BP) 
(Garvey, 2013). 
PHEN/TPM ER is generally well tolerated in the patient population. Common 
side effects include paresthesia, dry mouth, dizziness, dysgeusia, headache, constipation, 
and insomnia (Sweeting et al., 2014). Because both drugs act to affect the CNS, the 
combination therapy is associated with worsening mood disorders and suicidal ideation 
(Sweeting et al., 2014). There is no indication that individuals with mild depression on 
stable doses of antidepressants experience significant increases in moderate to severe 
depression or suicidality (Sweeting et al., 2014). In general, antiepileptic drugs, such as 
topiramate, include a precaution of increased risk of suicidal thoughts or behavior 
(Garvey, 2013). Furthermore, because of carbonic anhydrase inhibition due to topiramate, 
metabolic acidosis could be associated with this medication (Sweeting et al., 2014). 
When this condition is left untreated, chronic severe metabolic acidosis could lead to 
osteomalacia, osteoporosis, and renal calculi (Sweeting et al., 2014). Nevertheless, from 
the trials conducted, these side effects have not been observed. 
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Naltrexone/Bupropion ER: Opioid Receptor Antagonists 
and Dopamine/Norepinephrine Reuptake Inhibitors 
Naltrexone/bupropion (NB) was FDA-approved as a long-term obesity 
medication in 2014 (Kim, 2016). Each component used separately can induce weight 
loss; however, both medications used in conjunction can cause much more significant 
weight loss (Nuffer et al., 2016). Naltrexone as a monotherapy is an opioid receptor 
antagonist that is prescribed for the treatment of alcohol and opioid dependence (Wadden 
et al., 2011). Bupropion is a dopamine and norepinephrine reuptake inhibitor that is 
prescribed for the treatment of depression, smoking cessation, and attention-deficit 
hyperactivity disorder (ADHD) (Kim, 2016; Wadden et al., 2011).  
Similar to the many other new long-term obesity treatments currently on the 
market, the mechanism of action of NB is not well understood. Animal studies have 
suggested that NB acts on both the hypothalamus and the mesolimbic dopamine circuit 
(Golden, 2017). The hypothalamus is responsible for regulation of appetite, and the 
mesolimbic dopamine circuit is a component of the reward system (Golden, 2017). At the 
molecular level, researchers have postulated that the firing of POMC neurons in the 
arcuate nucleus of the hypothalamus is responsible for appetite suppression (Wadden et 
al., 2011). In this pathway, POMC neurons release α-MSH and β-endorphin (Wadden et 
al., 2011). The hormone α-MSH is responsible for the anorectic effect of the POMC 
activation, whereas the hormone β-endorphin causes autoinhibitory feedback by 
activating opioid receptors on POMC neurons (Wadden et al., 2011). It is suggested that 
the weight loss effects of bupropion may be attenuated by the β-endorphin-mediated 
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autoinhibitory feedback loop, and the addition of naltrexone may prevent the negative 
feedback loop on POMC neurons (Wadden et al., 2011). This action could facilitate 
continued weight loss or improve the ability to maintain the weight that has been lost 
already (Wadden et al., 2011). In general, this combination therapy of naltrexone and 
bupropion “modulates the CNS to elicit sustained appetite reduction and enhanced 
control of eating behavior” (McElroy et al., 2013).  
The combination therapy of NB has been studied in many clinical trials. In a 
Phase III clinical trial that enrolled 1742 subjects, individuals were randomized to 
different dosages of naltrexone and bupropion, such as 16 mg/360 mg (naltrexone 
ER/bupropion ER), 32 mg/360 mg (naltrexone ER/bupropion), or placebo (Kim, 2016). 
In this trial, scientists found that the placebo-subtracted weight loss at 56 weeks was 
3.7% and 4.8% for the lower and higher doses of the naltrexone formulation, respectively 
(Kim, 2016). When prescribed by a clinician, the recommended dose is 32 mg/360 mg 
(naltrexone/bupropion), and the medication is given in a complex dose titration (Gadde et 
al., 2018). The dose titration schedule is over a 4-week period, starting with one 8 mg/90 
mg tablet once daily and increasing to two 8 mg/90 mg tablets twice a day by week 4 
(Golden, 2017). 
Individuals taking NB often experience side effects such as nausea, constipation, 
headache, dizziness, vomiting, insomnia, dry mouth, and diarrhea (Kim, 2016). In RCTs 
conducted on NB, nausea was so frequent and bothersome that it led to a high dropout 
rate in the trials (Gadde et al., 2018). In addition, a slight increase in systolic and diastolic 
blood pressure and an increase in heart rate were reported in comparison with no change 
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in placebo arms (Kim, 2016). Because of these increases, the FDA required a 
cardiovascular outcomes trial (CVOT) to be conducted (Gadde et al., 2018). 
Unfortunately, this trial was discontinued as a result of inappropriate disclosure of data 
by the sponsor while the trial was ongoing (Gadde et al., 2018). Thus, information on the 
safety of NB on cardiovascular health is not currently known or available. Other 
information, however, shows that NB is contraindicated in patients with uncontrolled 
hypertension, binge-eating disorder, seizure disorders, chronic opioid use, or MAOI use 
within 14 days. NB is also contraindicated in patients who are currently undergoing 
discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs (Golden, 
2017). NB is known to interact with MAOIs as well as dopaminergic drugs and drugs that 
lower the seizure threshold (Golden, 2017). Because NB is categorized as a Category X 
drug, it is contraindicated for use in pregnant women (Golden, 2017). Furthermore, 
clinicians should monitor patients for depression and suicidal thoughts while taking NB 
(Golden, 2017). 
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III. COMPARISON OF PHARMACOTHERAPY FOR OBESITY TREATMENT 
 
In recent decades, scientists have shifted from short-term formulations to long-
term medications that could support extensive weight loss. Thus medications such as 
lorcaserin, PHEN/TPM ER, NB, and liraglutide have emerged on the market, each 
targeting specific pathways in the human body to regulate appetite and food intake in 
individuals. Considering the recent development of these treatments, it is understandable 
that researchers do not fully understand the mechanistic action of these drugs as well as 
long-term effects on human physiology.  
Clinicians must evaluate research findings and translate their understanding into 
appropriate treatment plans for their patients. In this instance, personalized medicine is 
important in prescribing drugs for individuals. Each FDA-approved drug has a unique 
mechanism of action and set of side effects that must be considered when prescribing to 
patients.  
Placebo-subtracted weight loss is important when comparing the efficacies of 
these medications. The purpose of obesity treatments is to administer a medication that 
causes the most weight loss. Placebo-subtracted weight loss serves as a value that 
expresses the percentage of weight that is lost when compared with the placebo. A higher 
percentage of weight loss is ideal. As shown in Table 2, PHEN/TPM ER was found to 
initiate the most weight loss, with patients losing 8.6% of body weight when taking the 
highest dose (Kim, 2016). Patients taking liraglutide were able to lose an average of 6% 
of body weight; however, the number of participants in this clinical trial was much lower 
than the trials conducted with the other medications (Kim, 2016). In patients taking the 
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highest dose of NB, the average amount of weight loss was 4.8%, while patients taking 
lorcaserin lost between 3% and 3.9% of body weight (Kim, 2016).  
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Table 2. Comparison of Placebo-Subtracted Weight Loss for Obesity Medications in 
Five Clinical Trialsa 
 
Medication Type of Trial Phase of Trial 
Duration 
of Trial 
(weeks) 
Number of 
Participants 
Placebo-
Subtracted 
Weight Loss 
(%) 
Orlistat 
Double-blind 
randomized 
control trial 
--- --- 3340 2.2  
Lorcaserin --- Phase III --- --- 3.0-3.9 
Phentermine/Topiramate ER Randomized control trial --- 56 2487 
6.6 (mid dose) 
8.6 (high dose) 
Naltrexone/Bupropion --- Phase III 56 1742 3.7 (low dose) 4.8 (high dose) 
Liraglutide --- Phase III 56 413 6.0 
a This table compares data obtained from various clinical trials that show the amount of 
placebo-subtracted weight loss which occurs when taking each medication. Taken from 
Kim (2016). 
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The FDA recommends that patients discontinue weight-loss medication if an 
individual has not lost 5% of body weight within 12 weeks because any weight loss after 
this period is unlikely. However, the data shown in Table 2 suggest that lorcaserin and 
NB do not fit these criteria for weight loss. Although it is easy to immediately discount 
these medications as ineffective, other factors are important when deciding what 
medication a clinician should prescribe to a patient. However, if the clinician simply 
wants to consider the medication that is most efficacious in terms of weight loss in the 
patient population, the data indicate that PHEN/TPM ER consistently initiates the most 
weight loss in patients.  
As with any medication, weight-loss drugs are accompanied with a series of 
precautions and contraindications that are important to acknowledge. Clinicians must 
practice personalized medicine here—understanding psychological, behavioral, and 
physiological components of a patient is essential to choosing the right treatment. For 
example, clinical trials conducted on liraglutide found that rats and mice were developing 
tumors of the thyroid. Even though this was only seen in animal models, patients with a 
history of medullary thyroid carcinoma or MEN II are cautioned not to take liraglutide 
(Gadde et al., 2018). In another instance, NB is contraindicated for use in patients with 
seizure disorders and eating disorders. Prescribing NB to patients with epilepsy could be 
dangerous to their health and cause fatality in extreme situations. Also, being aware of 
depression disorders is important because certain drugs may exacerbate the condition and 
cause moderate to severe mood change and increased suicidality. Table 3 compares the 
limitations for these medications. This information is essential for clinicians because it 
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allows them to see which medications to avoid prescribing to certain patients, and it helps 
them to better educate their patients on what to potentially expect when being treated 
with certain medications. 
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Table 3. Comparison of Adverse Events and Limitations for FDA-Approved Obesity 
Medicationsa 
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Table 3. Comparison of Adverse Events and Limitations for FDA-Approved Obesity 
Medicationsa  
Drug 
1-Year 
Weight 
Loss, 
Placebo-
Subtracted 
(%) 
Adverse Events Precautions Contraindications and Limitations 
Lorcaserin  3.0-3.6 
Monitor for 
symptoms of 
serotonin toxicity. 
Monitor for signs 
and symptoms of 
valvular heart 
disease. 
Safety of use in 
patients taking 
antidepressants is 
unknown. --- 
Liraglutide 4.0-5.4 
Nausea, vomiting, 
diarrhea, 
constipation, 
dyspepsia, 
abdominal pain, 
headache, fatigue, 
hypoglycemia, 
increased lipase. 
Causes thyroid c-
cell tumors in rats 
and mice. 
Discontinue if 
pancreatitis is 
suspected. 
Personal or family history 
of medullary thyroid 
carcinoma or multiple 
endocrine neoplasia 
syndrome type 2. Do not 
use with insulin or other 
GLP-1 agonists. 
Phentermine/Topiramate 8.6-9.3 
Paraesthesia, 
dizziness, 
insomnia, 
dysgeusia, 
constipation, dry 
mouth. 
Small increase in 
heart rate. Monitor 
electrolytes to 
detect metabolic 
acidosis and 
elevated creatinine. 
Monitor closely for 
depression, anxiety, 
and memory 
problems. 
Glaucoma, 
hyperthyroidism, within 2 
weeks of taking MAOIs. 
REMS requires negative 
pregnancy test before 
treatment and monthly 
thereafter to reduce the risk 
of teratogenicity.  
Naltrexone/Bupropion 3.3-4.8 
Nausea, vomiting, 
headache, 
dizziness, 
insomnia, dry 
mouth, diarrhea. 
Monitor for suicidal 
ideation and 
behavior. Monitor 
for increases in 
heart rate and blood 
pressure. Rare cases 
of hepatotoxicity. 
Uncontrolled hypertension; 
seizure disorders; chronic 
opioid use; anorexia 
nervosa or bulimia; during 
withdrawal from alcohol, 
barbiturate, 
benzodiazepines, and 
antiepileptic drugs; within 
2 weeks of taking MAOIs; 
coadministration with other 
bupropion-containing 
products. 
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a This table shows This table compares placebo-subtracted weight loss after one year, 
adverse events, precautions, and contraindications for the medications that are currently 
FDA-approved for weight loss. GLP-1 = glucagon-like peptide-1; MAOIs = monoamine 
oxidase inhibitors; REMS = risk evaluation and mitigation strategies. Taken from Gadde 
et al. (2018). 
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IV. CONCLUSION 
 
With the recent development of pharmacotherapy to address the obesity epidemic, 
there is not substantial literature to address long-term effects of these drugs on the human 
body. Thus, at this point in time, researchers and clinicians can only compare information 
that is given from the preliminary clinical trials. Whereas diseases such as T2DM have 
first-line medications like metformin, there is currently no agreement on which 
medication should be immediately given to treat obesity. Clinicians must evaluate each 
patient on a separate basis in order to decide which medication is appropriate for the 
specific condition. This directly agrees with the idea of personalized medicine, which is 
essential to providing optimal and personalized care to patients. For example, a patient 
with hyperthyroidism should not be given PHEN/TPM ER because it is contraindicated 
in this population; however, PHEN/TPM ER is the most efficacious medication at 
initiating weight loss. Clinicians must weigh the risks associated with this medication. In 
a patient with hyperthyroidism, a clinician may feel inclined to prescribe liraglutide 
because it is not contraindicated in this population but still causes a substantial amount of 
weight loss.  
The recent development of pharmacotherapy allows clinicians to treat a certain 
subsection of the population that was overlooked in the past. Being able to integrate 
medication with lifestyle modifications allows individuals to lose weight quicker while 
maintaining weight loss for a longer duration. Because development of long-term weight-
loss medications is a relatively recent effort, scientists and clinicians are unaware of the 
long-term physiological implications. Furthermore, a general consensus on which 
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medication should be prescribed as the primary treatment has not been reached. However, 
these four medications—liraglutide, lorcaserin, PHEN/TPM ER, and NB—are paving the 
way to increased treatment options for future generations, thus bringing society a step 
closer to decreasing the prevalence of obesity worldwide.  
 
 
  
	49 
REFERENCES 	
Adan, R. (2013). Mechanisms underlying current and future anti-obesity drugs. Trends in 
Neurosciences, 36(2), 133-140. doi:10.1016/j.tins.2012.12.001. 
 
Albuquerque, D., Nobrega, C., Manco, L., & Padez, C. (2017). The contribution of  
genetics and environment to obesity. British Medical Bulletin, 123(1), 159-173. 
doi:10.1093/bmb/ldx022. 
 
Angeli, F., & Shannon, R. (2014). Beyond Glycemic Control: Cardiovascular Effects of  
Incretin-Based Therapies. Cardiovascular Issues in Endocrinology,43, 144-157. 
doi:10.1159/000360598 
 
Barte, J., Veldwijk, J., Teixeira, P., Sacks, F., & Bemelmans, W. (2014). Differences in  
Weight Loss Across Different BMI Classes: A Meta-Analysis of the Effects of 
Interventions with Diet and Exercise . International Journal of Behavioral 
Medicine, 21(5), 784-793. doi:10.1007/s12529-013-9355-5. 
 
Cosentino, G., Conrad, A. O., & Uwaifo, G. I. (2013). Phentermine and topiramate for  
the management of obesity: a review. Drug Design, Development and Therapy, 7, 
267–278. http://doi.org.ezproxy.bu.edu/10.2147/DDDT.S31443 
 
Dietz, W., Baur, L., Hall, K., Puhl, R., Taveras, E., Uauy, R., & Kopelman, P. (2015).  
Management of obesity: improvement of health-care training and systems for 
prevention and care. Lancet, 385(9986), 2521-2533. doi:doi: 10.1016/S0140-
6736(14)61748-7. 
 
Farr, O., Upadhyay, J., Gavrieli, A., Camp, M., Spyrou, N., Kaye, H., . . . Mantzoros, C.  
(2016). Lorcaserin Administration Decreases Activation of Brain Centers in 
Response to Food Cues and These Emotion- and Salience-Related Changes 
Correlate with Weight Loss Effects: A 4-Week-Long Randomized, Placebo-
Controlled, Double-Blind Clinical Trial. Diabetes, 2943-2953. doi:10.2337/db16-
0635 
 
Frasca, D., & Blomberg, B. (2017). Adipose Tissue Inflammation Induces B Cell  
Inflammation and Decreases B Cell Function in Aging. Frontiers in Immunology. 
doi:10.3389/fimmu.2017.01003 
 
Gadde, K., Martin, C., Berthoud, H., & Heymsfield, S. (2018). Obesity: Pathophysiology  
and Management. Journal of the American College of Cardiology, 71(1), 69-84. 
doi:10.1016/j.jacc.2017.11.011. 
 
	50 
Gadde, K., & Pritham, R. Y. (2017). Pharmacotherapy of Obesity: Clinical Trials to  
Clinical Practice. Current Diabetes Reports, 17(5). doi:10.1007/s11892-017-
0859-2. 
 
Garvey, W. (2013). Phentermine and topiramate extended-release: a new treatment for  
obesity and its role in a complications-centric approach to obesity medical 
management. Expert Opinion on Drug Safety, 12(5), 741-756. 
doi:10.1517/14740338.2013.806481 
 
Golden, A. (2017). Current pharmacotherapies for obesity: A practical perspective.  
Journal of the American Association of Nurse Practitioners, 29(S1), 43-52. 
doi:10.1002/2327-6924.12519 
 
Graaf, C., Donnelly, D., Wootten, D., Lau, J., Sexton, P., Miller, L., . . . Wang, M.  
(2016). Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: 
A Long March to Therapeutic Successes. Pharmacological Reviews, 68(4), 954-
1013. doi:10.1124/pr.115.011395 
 
Gray, N., Picone, G., Sloan, F., & Yashkin, A. (2015). The Relationship between BMI  
and Onset of Diabetes Mellitus and its Complications. Southern Medical 
Journal, 108(1), 29-36. doi:10.14423/SMJ.0000000000000214 
 
Higgins, G., Silenieks, L., Rossmann, A., Rizos, Z., Noble, K., Soko, A., & Fletcher, P.  
(2012). The 5-HT2C Receptor Agonist Lorcaserin Reduces Nicotine Self-
Administration, Discrimination, and Reinstatement: Relationship to Feeding 
Behavior and Impulse Control. Neuropsychopharmacology, 37(5), 1177-1191. 
doi:10.1038/npp.2011.303. 
 
Jordan, J., Astrup, A., Engeli, S., Narkiewicz, K., Day, W. W., & Finer, N. (2014).  
Cardiovascular effects of phentermine and topiramate: a new drug combination 
for the treatment of obesity. Journal of Hypertension, 32(6), 1178–1188. 
http://doi.org.ezproxy.bu.edu/10.1097/HJH.0000000000000145 
 
Kalantari, N., Doaei, S., Keshavarz-Mohammadi, N., Gholamalizadeh, M., & Pazan, N.  
(2016). Review of studies on the fat mass and obesity-associated (FTO) gene 
interactions with environmental factors affecting on obesity and its impact	on	lifestyle	interventions	.	Arya	Atherosclerosis,	12(6),	281-290.	
 
Kaplan, U., Penner, S., Farrokhyar, F., Andruszkiewicz, N., Breau, R., Gmora, S., 
... Anvari, M. (2018). Bariatric Surgery in the Elderly Is Associated with Similar 
Surgical Risks and Significant Long-Term Health Benefits. Obesity Surgery
doi: 10.1007/s11695-018-3160-9. 
 
  
	51 
Kim, S. (2016). Drugs to treat obesity: do they work? Postgraduate Medical  
Journal,401-406. doi:10.1136/postgradmedj-2015-133388. 
 
Leung, A. W. Y., Chan, R. S. M., Sea, M. M. M., & Woo, J. (2017). An Overview of  
Factors Associated with Adherence to Lifestyle Modification Programs for 
Weight Management in Adults. International Journal of Environmental Research 
and Public Health, 14(8), 922. 
http://doi.org.ezproxy.bu.edu/10.3390/ijerph14080922 
 
Li, M., Qian, M., & Xu, J. (2017). Vascular Endothelial Regulation of Obesity- 
Associated Insulin Resistance. Frontiers in Cardiovascular Medicine. 4: 51 
doi:10.3389/fcvm.2017.00051 
 
Mancini, M., & de Melo, M. (2017). The burden of obesity in the current world and the  
New treatments available: focus on liraglutide 3.0 mg. Diabetology & Metabolic 
Syndrome. 9: 44. doi:10.1186/s13098-017-0242-0 
 
Manigault, K., & Thurston, M. (2016). Liraglutide: A Glucagon-Like Peptide-1 Agonist  
for Chronic Weight Management. The Consultant Pharmacist, 31(12), 685-697. 
doi:10.4140/TCP.n.2016.685. 
 
McElroy, S. L., Guerdjikova, A. I., Kim, D. D., Burns, C., Harris-Collazo, R.,  
Landbloom, R., & Dunayevich, E. (2013). Naltrexone/Bupropion Combination 
Therapy in Overweight or Obese Patients With Major Depressive Disorder: 
Results of a Pilot Study. The Primary Care Companion for CNS Disorders, 15(3), 
PCC.12m01494. http://doi.org.ezproxy.bu.edu/10.4088/PCC.12m01494 
 
Mehta, A., Marso, S., & Neeland, I. (2016). Liraglutide for weight management: a critical  
review of the evidence. Obesity Science & Practice, 3(1). doi:10.1002/osp4.84 
 
Meier, J. (2012). GLP-1 receptor agonists for individualized treatment of type 2 diabetes  
mellitus . Nature Reviews. Endocrinology, 8, 728-742. 
doi:10.1038/nrendo.2012.140 
 
Meldrum, D., Morris, M., & Gambone, J. (2017). Obesity pandemic: causes,  
consequences, and solutions--but do we have the will? Fertility and Sterility, 
107(4), 833-839. doi:10.1016/j.fertnstert.2017.02.104. 
 
Morris, M., Beilharz, J., Maniam, J., Reichelt, A., & Westbrook, R. (2015). Why is  
obesity such a problem in the 21st century? The intersection of palatable food, 
cues, and reward pathways, stress, and cognition. Neuroscience & Biobehavioral 
Reviews, 58, 36-45. doi:10.1016/j.neubiorev.2014.12.002. 
 
  
	52 
Nuffer, W., & Trujillo, J. (2015). Liraglutide: A New Option for the Treatment of  
Obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug 
Therapy, 35(10), 926-934. doi:10.1002/phar.1639 
 
Nuffer, W., Trujillo, J., & Megyeri, J. (2016). A Comparison of New Pharmacological  
Agents for the Treatment of Obesity. Annals of Pharmacotherapy, 50(5), 376-388. 
doi:10.1177/1060028016634351 
 
Pappachan, J., & Viswanath, A. (2017). Medical Management of Diabesity: Do We Have  
Realistic Targets? Current Diabetes Reports. doi:10.1007/s11892-017-0828-9. 
 
Redman, L., & Ravussin, E. (2010). Lorcaserin for the treatment of obesity. Drugs  
Today, 46(12), 901-910. doi:10.1358/dot.2010.46.12.1556433 
 
Sandouk, Z., & Lansang, M. C. (2017). "Diabetes with obesity—Is there an ideal diet?"  
Cleveland Clinic Journal of Medicine 84, no. 7. doi: 10.3949/ccjm.84.s1.02. 
 
Santilli, F., Simeone, P. G., Guagnano, M. T., Leo, M., Maccarone, M. T., Di  
Castelnuovo, A., . . . Consoli, A. (2017). Effects of Liraglutide on Weight Loss, 
Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or 
Early Type 2 Diabetes. Diabetes Care,40(11), 1556-1564. doi: 10.2337/dc17-
0589. 
 
Sheikh, A., Nasrullah, A., Haq, S., Akhtar, A., Ghazanfar, H., Nasir, A., . . . Naqvi, S.  
(2017). The Interplay of Genetics and Environmental Factors in the Development 
of Obesity. Cureus, 9(7). doi:10.7759/cureus.1435. 
 
Skov, J. (2014). Effects of GLP-1 in the Kidney. Reviews in Endocrine and Metabolic  
Disorders,15(3), 197-207. doi:10.1007/s11154-014-9287-7. 
 
Skow, M., Bergmann, N., & Knop, F. (2016). Diabetes and obesity treatment based on  
dual incretin receptor activation: ‘twincretins’. Diabetes, Obesity and Metabolism. 
18(9), 847-854. doi:10.1111/dom.12685 
 
Smith, S., Prosser, W., Donahue, D., Morgan, M., Anderson, C., & Shanahan, W. (2009).  
Lorcaserin (APD356), a Selective 5-HT2C Agonist, Reduces Body Weight in 
Obese Men and Women. Obesity, 17(3), 494-503. doi:10.1038/oby.2008.537. 
  
Stolarczyk, E. (2017). Adipose tissue inflammation in obesity: a metabolic or immune  
response? Current Opinion in Pharmacology, 37, 35-40. doi:
            10.1016/j.coph.2017.08.006. 
  
	53 
 
Sweeting, A., Tabet, E., Caterson, I., & Markovic, T. (2014). Management of obesity and  
cardiometabolic risk – role of phentermine/extended release topiramate. Diabetes, 
Metabolic Syndrome and Obesity: Targets and Therapy, 7, 35-44. 
doi:10.2147/DMSO.S38979 
 
Tremmel, M., Gerdtham, U., Nilsson, P., & Saha, S. (2017). Economic Burden of  
Obesity: A Systematic Literature Review. International Journal of 
Environmental Research and Public Health, 14(4). doi:10.3390/ijerph14040435 
 
van Bloemendaal, L., Veltman, D., Ten Kulve, J., Drent, M., Barkhof, F., Diamant, M.,  
& IJzerman, R. (2015). Emotional eating is associated with increased brain 
responses to food-cues and reduced sensitivity to GLP-1 receptor activation. 
Obesity, 23(10), 2075-2082. doi:10.1002/oby.21200. 
 
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O’Neil, P. M., …  
Dunayevich, E. (2011). Weight Loss With Naltrexone SR/Bupropion SR 
Combination Therapy as an adjunct to Behavior Modification: The COR-BMOD 
Trial. Obesity, 19(1), 110–120. 
http://doi.org.ezproxy.bu.edu/10.1038/oby.2010.147 
 
Zhao, W., Ware, E., He, Z., Kardia, S., Faul, J., & Smith, J. (2017). Interaction between  
Social/Psychosocial Factors and Genetic Variants on Body Mass Index: A Gene-
Environment Interaction Analysis in a Longitudinal Setting. International Journal 
of Environmental Research and Public Health, 14(10). 
doi:10.3390/ijerph14101153 
 Zietek,	T.,	&	Rath,	E.	(2016).	Inflammation	Meets	Metabolic	Disease:	Gut	Feeling		Mediated	by	GLP-1.	Frontiers	in	Immunology, 7, 154.	doi:10.3389/fimmu.2016.00154	
  
	54 
VITA 
	55 
